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Abstract
Most psychiatric disorders are moderately to highly heritable. The degree to which genetic
variation is unique to individual disorders or shared across disorders is unclear. To examine shared
genetic etiology, we use genome-wide genotype data from the Psychiatric Genomics Consortium
(PGC) for cases and controls in schizophrenia, bipolar disorder, major depressive disorder, autism
spectrum disorders (ASD) and attention-deficit/hyperactivity disorder (ADHD). We apply
univariate and bivariate methods for the estimation of genetic variation within and covariation
between disorders. SNPs explained 17–29% of the variance in liability. The genetic correlation
calculated using common SNPs was high between schizophrenia and bipolar disorder (0.68 ± 0.04
s.e.), moderate between schizophrenia and major depressive disorder (0.43 ± 0.06 s.e.), bipolar
disorder and major depressive disorder (0.47 ± 0.06 s.e.), and ADHD and major depressive
disorder (0.32 ± 0.07 s.e.), low between schizophrenia and ASD (0.16 ± 0.06 s.e.) and non-
significant for other pairs of disorders as well as between psychiatric disorders and the negative
control of Crohn’s disease. This empirical evidence of shared genetic etiology for psychiatric
disorders can inform nosology and encourages the investigation of common pathophysiologies for
related disorders.
The current classification of psychiatric disorders reflects clinical syndromes with largely
unknown etiology and is based on historical descriptions provided by prominent clinicians
over the last 125 years. Family (including twin and adoption) studies provide consistent
evidence that genetic factors are involved in these syndromes1. In principle, family studies
allow quantification of the shared genetic etiology of disorders, through the estimation of
heritability (the proportion of variance in liability attributable to additive genetic factors),
and the genetic correlation between them. However, difficulties in ascertaining samples of
sufficient size mean that there are few estimates of genetic correlations. Nonetheless, family
studies suggest correlated familial genetic liabilities to bipolar disorder and schizophrenia2,3,
bipolar disorder and major depressive disorder2,3, and ASD and ADHD4–6 (Supplementary
Table 1). Phenotypic and genetic overlap has also been suggested for ASD and
schizophrenia7–11, ASD and bipolar disorder9, bipolar disorder and ADHD12, and major
depressive disorder and ADHD13. Some of these relationships have been supported by
recent evidence of shared molecular risk factors14–16, but the extent of these relationships
remains unclear, given the small proportion of risk associated with individually identified
variants.
The genomics era provides new opportunities to explore the shared genetic etiology of
disorders. Genome-wide association studies (GWAS) assess common genetic
NIH Public Access
Author Manuscript
Nat Genet. Author manuscript; available in PMC 2014 September 01.
Published in final edited form as:
Nat Genet. 2013 September ; 45(9): 984–994. doi:10.1038/ng.2711.
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
polymorphisms (for example, SNPs) at several hundred thousand positions in the genome.
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The experimental paradigm of GWAS involves the identification of individual variants
associated with case-control status17. However, these data can also be used to estimate the
total variance in liability explained by SNPs (SNP heritability, ) through the estimation
of genetic similarities (relationships) between cases and controls using SNP genotypes18,19.
The pairwise genetic relationships that contribute to the estimate are very small, but the
large number of pairwise relationships in a case-control sample generates estimates with
reasonable precision. The  value is an estimate of the total variance in liability to disease
explained by SNPs together. Genetic variation is estimated when case-case pairs and
control-control pairs are, on average, more similar across the genome than case-control
pairs. The  value is a lower bound for total narrow-sense heritability, as the former
cannot include contributions from causal variants not tagged by the measured SNPs, mostly
less common and rare causal variants. A bivariate extension20 of these genome-wide
methods estimates the genetic correlation (rg SNP) explained by SNPs between case-control
samples collected independently for two disorders (Online Methods). The correlation is
positive when the cases of one disorder show higher genetic similarity to the cases of the
other disorder than they do to their own controls. A negative correlation is possible if the
cases of one disorder are less similar across the genome to the cases of another disorder than
they are to controls of the other disorder. A genetic correlation of zero is estimated if the
genome-wide relationship between cases of one disorder is the same with the cases as with
the controls of another disorder. As a correlation, a high rg SNP value is achieved when the
covariance term between the traits is similar in magnitude to the variance terms. Therefore,
we also report the SNP-based coheritability of pairs of disorders, which is the covariance
between disorders on the liability scale and allows comparison of the shared liability
attributable to SNPs on the same scale as . Here we apply univariate and bivariate
methods to the five disorders of the PGC—schizophrenia21, bipolar disorder22, major
depressive disorder23, ASD24,25 and ADHD26—analyzed in the PGC Cross-Disorder Group
association study25, together with additional ADHD data sets27–30 (Table 1).
RESULTS
SNP heritabilities for the five disorders
In our linear mixed model, we estimate the variance in case-control status explained by
SNPs18 (heritability on the observed scale; CC estimates in Table 1). Cases in case-control
samples are highly ascertained compared to in the population, and, because the cohorts for
different disorders had different proportions of cases, CC estimates were difficult to interpret
and compare. For this reason, we report  values on the liability scale, in which a linear
transformation18 is applied based on a user-specified estimate of the risk of the disorder in
the study base population (disorder risk, K). For each disorder, we considered three values of
K (Table 1), and we converted  values to predicted risk to first-degree relatives
(ţ1st SNP) given K. We benchmarked the ţ1st SNP risk values to risk to first-degree relatives
(ţ1st), consistent with estimates of heritability reported from family studies given K. Our
estimates of ţ1st SNP values were robust, and our estimates of  values were reasonably
robust, to the likely range of K values and show that a key part of the heritabilities or
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familial risk estimated from family studies is associated with common SNPs. Twice the
standard error of estimates approximates the magnitude of the parameter that is possible to
detect as being significantly different from zero, given the available sample sizes31.
SNP coheritabilities and SNP correlations (rg SNP)
The relationships between disorders were expressed as SNP-based coheritabilities (Fig. 1).
The rg SNP value was high between schizophrenia and bipolar disorder at 0.68 (0.04 standard
error (s.e.)), moderate between schizophrenia and major depressive disorder at 0.43 (0.06
s.e.), bipolar disorder and major depressive disorder at 0.47 (0.06 s.e.), and ADHD and
major depressive disorder at 0.32 (0.07 s.e.), low between schizophrenia and ASD at 0.16
(0.06 s.e.) and non-significant for other pairs of disorders (Supplementary Table 1). The
rg SNP value for correlation is expected to be equal to the rg value from family studies only if
genetic correlation is the same across the allelic frequency spectrum and if the linkage
disequilibrium (LD) between genotyped and causal variants is similar for both disorders.
The sample size for ASD was the smallest but still could detect correlations of >|0.18|
different from zero in bivariate analyses with all other disorders.
Our results provide empirical evidence that schizophrenia, bipolar disorder and major
depressive disorder have shared genetic etiology. Because some schizophrenia and bipolar
disorder cohorts were collected in the same clinical environments, we investigated the
possible impact of the non-independent collection of schizophrenia and bipolar disorder
samples sets but found no significant change in the estimates related to this (Supplementary
Table 2). The correlation between schizophrenia and ASD was significant but small (0.16,
0.06 s.e.; P = 0.0071). In general, our analyses suggested that, whereas common genetic
variants contribute to both childhood-onset disorders (ASD and ADHD) and disorders
usually diagnosed after childhood (schizophrenia, bipolar disorder and major depressive
disorder), the sharing of common variants between these groups is modest.
The pattern of our results (in which pairs of disorders demonstrated genetic overlap) was
consistent with polygenic profile score32 results from PGC cross-disorder analyses25. The
profile score method uses SNP associations from one disorder to construct a linear predictor
in another disorder. The profile scores explained small but significant proportions of the
variance25, expressed as Nagelkerke’s R2 (maximum of 2.5% between schizophrenia and
bipolar disorder). To achieve high R2 values requires accurate estimation of the effect sizes
of individual SNPs and depends on the size of the discovery sample. In contrast, our
approach uses SNPs to estimate genome-wide similarities between pairs of individuals,
resulting in unbiased estimates of the relationships between disorders, with larger sample
sizes generating smaller standard errors for the estimates. Our estimates were on the liability
scale, allowing direct comparison to genetic parameters estimated in family studies, whereas
a genetic interpretation of Nagelkerke’s R2 values is less straightforward33.
Genomic partitioning of SNP heritabilities and coheritabilities
The heritabilities explained by SNPs can be partitioned according to SNP annotation by the
estimation of genetic similarity matrices from multiple, non-overlapping SNP sets. For the
five disorders and the five disorder pairs showing significant SNP correlation, we partitioned
Page 4
Nat Genet. Author manuscript; available in PMC 2014 September 01.
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
the  and SNP-based coheritabilities explained by functional annotation, allocating SNPs
to one of three sets: (i) SNPs in genes preferentially expressed in the central nervous system
(CNS+)34,35, (ii) SNPs in other genes and (iii) SNPs not in genes, with genes defined by 50-
kb boundaries extending from their start and stop positions. The SNPs in the CNS+ gene set
represented 0.20 of the total set, both in number and megabases of DNA. However, the
proportion of the variance explained by SNPs attributable to this SNP set was significantly
greater than 0.20 for schizophrenia (0.30; P = 7.6 × 10−8) and bipolar disorder (0.32; P = 5.4
× 10−6) and for schizophrenia and bipolar disorder coheritability (0.37; P = 8.5 × 10−8) (Fig.
2 and Supplementary Table 3). For other disorders or pairs of disorders, the estimates
explained by CNS+ SNPs did not differ from the values expected by chance (Supplementary
Table 3), although their large standard errors suggest that we cannot address this question
with precision. For data from the schizophrenia and bipolar disorder pair, we also partitioned
the heritabilities explained by SNPs by minor allele frequency (MAF) (Supplementary Table
4) and by chromosome (Supplementary Fig. 1). The high standard errors on estimates
limited interpretation, but the results are consistent with a polygenic architecture comprising
many common variants of small effect dispersed throughout the genome. The MAF
partitioning suggests that a key part of the variance explained by SNPs is attributable to
common causal variants (this was investigated in detail for schizophrenia35), but the low
contribution to the total variance explained by SNPs with MAF of <0.1 reflects, at least in
part, under-representation of SNPs with low MAFs in the analysis (minimum MAF = 0.01)
relative to those present in the genome.
Within-disorder heterogeneity
To benchmark the estimates of genetic sharing across disorders, we estimated sharing
between data subsets for the same disorder. We split the data for each disorder into two or
three independent sets and estimated  values for each subset and the SNP-based coher-
itability between each pair of subsets within a disorder (Fig. 3a and Supplementary Table 5).
The estimates of  from the data subsets were typically higher than the  estimate
from the combined sample; we note that published estimates from individual cohorts of
bipolar disorder18, major depressive disorder36 and ASD37 were also higher. Because both
traits in these data subset bivariate analyses are for the same disorder, the SNP-based
coheritability is also an estimate of  for the disorder, but these estimates were generally
lower than the estimates of SNP-based heritability from individual data subsets. These
results generated SNP-based correlations that were less than 1, sometimes significantly so
(Supplementary Table 5). The SNP-based correlation between schizophrenia and bipolar
disorder (0.68, 0.04 s.e.) was of comparable magnitude to the SNP-based correlations
between bipolar disorder data sets (0.63, 0.11 s.e.; 0.88, 0.09 s.e.; and 0.55, 0.10 s.e.; Fig.
3a,b, SNP-based coherit-abilities), adding further weight to the conclusion that
schizophrenia and bipolar disorder may be part of the same etiological spectrum.
The estimates of heritability from both univariate (Fig. 3a, red and pink bars) and bivariate
(Fig. 3a, blue bars) analyses are more heterogeneous for bipolar disorder, major depressive
disorder and ADHD than they are for schizophrenia and ASD. Several factors could explain
why SNP-based heritabilities from univariate analyses of a single data set could generate
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higher estimates than bivariate analyses of independent data sets35, including loss of real
signal or dilution of artifacts. Loss of real signal might occur because individual cohorts are
more homogeneous, both phenotypically (for example, owing to use of the same assessment
protocols) and genetically (for example, because LD between causal variants and analyzed
SNPs might be higher within than between cohorts). Artifacts could also generate consistent
differences in case genotypes relative to control genotypes within case-control data sets. In
the derivation of our methodology18, we emphasized that any factors making SNP
genotypes of cases more similar to those of other cases and making the genotypes of
controls more similar to those of other controls would produce SNP-based heritability. The
fitting as covariates of principal components derived from the SNP data corrects both for
population stratification and for genotyping artifacts, but residual population stratification
could remain, although this bias should be small38. Partitioning SNP-based heritability by
chromosome in analyses where each chromosome was fitted individually compared to
analyses where all chromosomes were fitted jointly is an empirical strategy to assess
residual stratification35,39, and we found no evidence of this type of stratification here
(Supplementary Fig. 1). Stringent quality control (as applied here) helps to remove artifacts,
but artifactual differences between cases and controls might remain, particularly for data sets
in which cases and controls have been genotyped independently40. As more data sets
accumulate, the contributions from artifacts are diluted because the random directional
effects of artifacts (including population stratification) are not consistent across data sets.
For this reason, significant SNP-based coheritabilities between subsets of the same disorder
are unlikely to reflect artifacts and provide a lower bound for SNP-based heritability.
Pseudocontrols
One strategy adopted in GWAS to guard against artifacts from population stratification is to
genotype family trio samples (cases and their parents) and then analyze the data as a case-
control sample, with controls generated as genomic complements of the cases (pseudo-
controls). ADHD subset 1 and most of the ASD sample comprised case-pseudocontrol
samples and, consistent with this strategy limiting the impact of artifacts from population
stratification or genotyping, it is noted that the lowest SNP-based heritability for the five
psychiatric disorders was for ASD and that the estimate of SNP-based heritability was lower
for ADHD subset 1 than for ADHD subset 2. However, under a polygenic model, assortative
mating41 or preferential ascertainment of multiplex families could diminish the expected
mean difference in liability between pseudocontrols and cases37, which would result in an
underestimation of SNP-based heritability from case-pseudocontrol compared to case-
control analyses and would also result in nonzero estimates of SNP-based heritability from
pseudocontrol-control analyses, as shown in analysis of ASD data37.
SNP-based coheritabilities with Crohn’s disease
As a negative control analysis, we conducted bivariate analyses between each of the PGC
data sets and Crohn’s disease samples from the International IBD Genetics Consortium
(IIBDGC)42. Although onset of major depressive disorder is not uncommon after diagnosis
with Crohn’s disease43 and although gastrointestinal pathology is a common comorbidity
with ASD44, there is no strong evidence of a familial relationship between psychiatric
disorders and Crohn’s disease. Despite substantial hSNP 2 values for Crohn’s disease (0.19,
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0.01 s.e.), none of the SNP-based coheritabilities with the psychiatric disorders differed
significantly from zero (Fig. 3c, Supplementary Table 6 and Supplementary Note). Lastly,
genomic partitioning by annotation of the variance in Crohn’s disease explained by SNPs
showed, as expected, no excess of variance attributable to SNPs in the CNS+ gene set (Fig.
2). Our results provide no evidence of common genetic pleiotropy in Crohn’s disease and
ASD, consistent with a non-genetic, for example, microbial45, explanation for the
comorbidity of gastrointestinal symptoms in ASD.
Potential impact of misclassification of disorders
Misclassification among disorders could inflate estimates of genetic correlation and/or
coheritability46. Indeed, some level of misclas-sification in psychiatric disorders is expected.
For example, longitudinal studies47,48 of first admissions with psychosis showed that, with
long-term follow-up, ~15% of subjects initially diagnosed with bipolar disorder were
rediagnosed with schizophrenia, whereas ~4% of schizophrenia diagnoses were reclassified
as bipolar disorder. Cases selected for GWAS contributing to PGC are more likely to have
achieved a stable diagnosis compared to first-admission cases. However, assuming these
levels of misclassification, the genetic correlation between bipolar disorder and
schizophrenia for true diagnoses is still high, estimated46 to be 0.55. Likewise, because a
modest proportion of cases diagnosed with major depressive disorder, when followed over
time, ultimately meet criteria for bipolar disorder49, our estimated genetic correlation
between these two disorders may be modestly inflated by misclassification. However, if
moderate-to-high genetic correlations between the major adult disorders are true, then
overlapping symptoms and misdiagnosis among these disorders might be expected. The
rg SNP value between schizophrenia and major depressive disorder is also unlikely to reflect
misdiagnosis because misclassification between these disorders is rare49. Excluding 5 of the
18 PGC schizophrenia cohorts containing schizoaffective disorder cases21 (Supplementary
Table 7) or major depressive disorder cohorts ascertained from community rather than
clinical settings (Supplementary Table 8) had little impact on rg SNP estimates.
DISCUSSION
Our results show direct, empirical, quantified molecular evidence for an important genetic
contribution to the five major psychiatric disorders. The  estimates for each disorder—
schizophrenia, 0.23 (0.01 s.e.), bipolar disorder, 0.25 (0.01 s.e.), major depressive disorder,
0.21 (0.02), ASD, 0.17 (0.02 s.e.) and ADHD, 0.28 (0.02 s.e.)—are considerably less than
the heritabilities estimated from family studies (Table 1). Yet, they show that common SNPs
make an important contribution to the overall variance, implying that additional individual,
common SNP associations can be discovered as sample size increases50.  values are a
lower bound for narrow-sense heritability because they exclude contributions from some
causal variants (mostly rare variants) not associated with common SNPs. Although SNP-
based heritability estimates are similar for major depressive disorder and other disorders,
much larger sample sizes will be needed, as high risk for a disorder implies lower power for
equal sample size51. The  values are all lower than those reported for height (0.45, 0.03
s.e.)39, but the estimates are in the same ballpark as those reported for other complex traits
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and diseases using the same quality control pipeline, such as for body mass index (BMI)
(0.17, 0.03 s.e.)39, Alzheimer’s disease (0.24, 0.03 s.e.), multiple sclerosis (0.30, 0.03 s.e.)
and endometriosis (0.26, 0.04 s.e.)40.
Our results show molecular evidence of the sharing of genetic risk factors across key
psychiatric disorders. Traditionally, quantification of the genetic relationship between
disorders has been thwarted by the need for cohorts of families or twins assessed for
multiple disorders. Problems of achieving genetically informative samples of sufficient size
and without associated ascertainment biases for the rarer psychiatric disorders have meant
that few studies have produced meaningful estimates of genetic correlations. Notably, our
estimates of heritability and genetic correlation are made using very distant genetic
relationships between individuals, both within and between disorders, so that shared
environmental factors are unlikely to contaminate our estimates. Likewise, our estimates are
unlikely to be confounded by non-additive genetic effects, as the coefficients of non-additive
genetic variance between very distant relatives are negligible52.
The estimates of SNP-based genetic correlation (rg SNP) between disorders reflect the
genome-wide pleiotropy of variants tagged by common SNPs, and whether these are the
same as correlations across the allelic frequency spectrum may differ between pairs of
disorders. For example, a high rg SNP value but a low genetic correlation estimated from
family studies (rg) could indicate that the same common variants contribute to genetic
susceptibility for both disorders, although the diagnostic-specific variants are less common
variants. For this reason, the comparison of rg SNP with rg estimated from family studies is
not straightforward. Nonetheless, we benchmark our estimates in this way, calculating the
increased risk of disorder B in first-degree relatives of probands with disorder A (ţA,B) from
the rg SNP value to allow comparison with literature values (Supplementary Table 1). A
meta-analysis53 reported increased risk of bipolar disorder in first-degree relatives of
probands with schizophrenia compared to first-degree relatives of control probands
(ţSCZ,BPD) of 2.1, which implies a maximum genetic correlation between the disorders of
0.3 (assuming that the disorder risks for schizophrenia and bipolar disorder are both 1% and
their heritabilities are 81% and 75%, respectively; Table 1). However, a large-scale Swedish
family and adoption study54 estimated the genetic correlation between schizophrenia and
bipolar disorder to be +0.60, similar to that found here. Profiling scoring analysis using
genome-wide SNPs32 was the first method to clearly demonstrate a genetic relationship
based on molecular data, but quantification as a genetic correlation was not reported. The
evidence of shared genetic risk factors for schizophrenia and bipolar disorder was
strengthened by our analyses of the CNS+ gene set in which we saw a clear enrichment in
variants shared by these two disorders.
Our finding of a substantial rg SNP of +0.43 between schizophrenia and major depressive
disorder is notable and contrary to conventional wisdom about the independence of familial
risk for these disorders. However, because major depressive disorder is common, even a
high genetic correlation implies only modest incremental risk. Assuming the disorder risks
and heritabilities for schizophrenia and major depressive disorder given in Table 1, then the
genetic correlation between them of 0.43 predicts increased risk of major depressive
disorder in first-degree relatives of probands with schizophrenia compared to first-degree
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relatives of control probands (ţSCZ,MDD) of 1.6. In fact, meta-analysis of five interview-
based research studies of families are broadly consistent with our results (ţSCZ,MDD = 1.5,
95% confidence interval (CI) = 1.2–1.8; Supplementary Table 9), suggesting that familial
coaggregation of major depressive disorder and schizophrenia reflects genetic effects rather
than resulting from living in a family environment that includes a severely ill family
member. If replicated by future work, our empirical molecular genetic evidence of a partly
shared genetic etiology for schizophrenia and major depressive disorder would have key
nosological and research implications, incorporating major depressive disorder as part of a
broad psychiatric genetic spectrum. A shared genetic etiology for bipolar disorder and major
depressive disorder has been shown in family studies2,3, but the rg SNP value of 0.47 was
lower than the estimate of 0.65 from a twin study55.
Our results show a small but significant rg SNP value between schizophrenia and ASD. A
lower genetic correlation between schizophrenia and ASD than between schizophrenia and
bipolar disorder is consistent with Swedish national epidemiological studies, which reported
higher odds ratios in siblings for schizophrenia and bipolar disorder54 than for schizophrenia
and ASD9. These results imply a modest overlap of common genetic etiological processes in
these two disorders, consistent with emerging evidence from the discovery of copy number
variants, in which both shared variants (for example, 15q13.3, 1q2.1 and 17q12
deletions56,57) and mutations in the same genes although with different variants (deletions
associated with schizophrenia and duplications associated with autism and vice-versa10).
The small ASD sample size thwarted attempts at further explorative partitioning of the SNP-
based coheritability for schizophrenia and ASD.
The lack of overlap between ADHD and ASD is unexpected and is not consistent with
family and data linkage studies, which indicate that the two disorders share genetic risk
factors5,6,58,59. Some rare copy number variants are seen in both disorders16. As noted
above, the use of pseudocontrols for many of the ASD and ADHD cohorts may affect all
results for these disorders. Ideally, we would investigate the impact of pseudocontrols, given
the hierarchical diagnostic system (autism but not autism spectrum is an exclusion criterion
for most ADHD data sets), on estimates of SNP-based coheritability, but the small ASD
sample size prohibits such analyses. We also found no overlap between ADHD and bipolar
disorder, despite support from meta-analysis results of an increased risk for ADHD in
relatives of individuals with bipolar disorder I (a subtype of bipolar disorder with more
extreme manic symptoms than the other major bipolar disorder subtype) and an increased
risk for bipolar disorder I in relatives of individuals with ADHD12. These findings could
mean that the familial link between the two disorders is mediated by environmental risk
factors or that shared genetic factors are not part of the common allelic spectrum.
Alternatively, the etiological link between ADHD and bipolar disorder might be limited to
bipolar disorder I or early-onset bipolar disorder12, which, therefore, is difficult for us to
detect. Our finding of genetic overlap between ADHD and major depressive disorder is
consistent with evidence from studies showing increased rates of ADHD in the families of
depressed probands and increased rates of depression in families of probands with
ADHD12,13.
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Our results should be interpreted in the context of four potentially important methodological
limitations. First, any artifacts that make SNP genotypes more similar between cases than
between cases and controls could inflate estimates of SNP-based heritability18, but to a
much lesser extent for SNP-based coheritability. Second, the sample sizes varied
considerably across the five disorders. Although  values are expected to be unbiased,
estimates from smaller samples are accompanied by larger standard errors, blurring their
interpretation. Third, although applying similar diagnostic criteria, the clinical methods of
ascertainment and the specific study protocols, including which specific interview
instruments were employed, varied across sites. We cannot now determine the degree to
which our results might have been influenced by between-site differences in the kinds of
patients seen or in their assessments. Fourth, by combining samples from geographic
regions, contributions from less common associated variants specific to particular
populations are diluted compared to what would have been achieved if the same sample size
had been ascertained from a single homogeneous population.
In summary, we report SNP-based heritabilities that are significantly greater than zero for all
five disorders studied. We have used the largest psychiatric GWAS data sets currently
available, and our results provide key pointers for future studies. Our results demonstrate
that the dearth of significant associations from psychiatric GWAS so far, particularly for
major depressive disorder, ASD and ADHD, reflects lack of power to detect common
associated variants of small effect rather than the absence of such variants. Hence, as sample
sizes increase, the success afforded to other complex genetic diseases50 in increasing the
understanding of their etiologies is achievable for psychiatric disorders, as is already being
shown for schizophrenia60. We also provide evidence of substantial sharing of the genetic
risk variants tagged by SNPs between schizophrenia and bipolar disorder, bipolar disorder
and major depressive disorder, schizophrenia and major depressive disorder, ADHD and
major depressive disorder, and, to a lesser extent, between schizophrenia and ASD. Our
results will likely contribute to the efforts now under way to base psychiatric nosology on a
firmer empirical footing. Furthermore, they will encourage investigations into shared
pathophysiologies across disorders, including potential clarification of common therapeutic
mechanisms.
ONLINE METHODS
Data and quality control
A summary of the data available for analysis is listed in Table 1 and comprise data used in
the PGC–Cross-Disorder Group analysis25 together with newly available ADHD
samples27–30. Data upload to the PGC central server follows strict guidelines to ensure local
ethics committee approval for all contributed data (PGC; see URLs). Data from all study
cohorts were processed through the stringent PGC pipeline25. Imputation of autosomal SNPs
used CEU (Utah residents of Northern and Western European ancestry) and TSI (Toscani in
Italia) HapMap Phase 3 data as the reference panel21. For each analysis (univariate or
bivariate), we retained only SNPs that had MAF of >0.01 and imputation R2 of >0.6 in all
contributing cohort subsamples (imputation cohorts). Different quality control strategies
were investigated in detail for the raw and PGC imputed genotyped data of the International
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Schizophrenia Consortium, a subset of the PGC schizophrenia sample35. The Crohn’s
disease samples from IIBDGC42 were processed through the same quality control and
imputation pipeline as the PGC data, generating a data set of 5,054 cases and 11,496
controls from 6 imputation cohorts.
In each analysis, individuals were excluded to ensure that all cases and controls were
completely unrelated in the classical sense, so that no pairs of individuals had a genome-
wide similarity relationship greater than 0.05 (equivalent to about second cousins). This
procedure removed ancestry outliers (over and above those already removed in the PGC
quality control pipeline; Supplementary Fig. 2) and ensured that overlapping control sets
were allocated randomly between disorders in the bivariate analyses. Exact numbers of cases
and controls used in each analysis are listed in Supplementary Tables 1–8.
Linear mixed model for estimation of SNP-based heritability and coherit-ability
We used the methods presented in Lee et al.18,35. Briefly, we estimated the variance in case-
control status explained by all SNPs using a linear mixed model
where y is a vector of case (y = 1) or control (y = 0) status (the observed scale), Ś is a vector
for fixed effects of the overall mean (intercept), sex, sample cohort and 20 ancestry principal
components, g is the vector of random additive genetic effects based on aggregate SNP
information and e is a vector of random error effects. X is an incidence matrix for the fixed
effects relating these effects to individuals. The variance structure of phenotypic
observations is
where  is additive genetic variance tagged by the SNPs,  is error variance, A is the
realized similarity relationship matrix estimated from SNP data19 and I is an identity matrix.
All variances were estimated on the observed case-control scale and were transformed to the
liability scale, which requires specification of the disorder risk K to estimate . Risk to
first-degree relatives was calculated from K and  on the basis of the liability threshold
model62.
The bivariate analyses used a bivariate extension of equation (1) (ref. 20). The two traits
were measured in different individuals, but the equations were related through the genome-
wide similarities estimated from SNPs. Genetic and residual variances for the traits were
estimated as well as the genetic covariance ūg12. The genetic correlation coefficient (rg) was
calculated by (ūg12/(ūg1ūg2)) and is approximately the same on the observed case-control
scale as on the liability scale20 and so does not depend on specifications of K. The
covariance ūg12 can be transformed to the liability scale, accounting for assumed disorder
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risks and proportions of cases and controls in the samples of each disorder20, and it equals
the coheritability52 rgh1h2. We used the approximated ů2 test statistic (estimate/s.e.)2 to test
whether estimates were significantly different from zero. We checked that this simple
approximation agreed well with the more formal and computer-intensive likelihood ratio test
for several examples. Heterogeneity of SNP-based heritabilities was tested using Cochran’s
Q (ref. 63) and Higgins’ I2 (ref. 64) values, acknowledging potential non-independence of
the six estimates (three subsets plus three subset pairs).
Disorder risk for the study-based population (disorder risk, K)
Estimates of  and SNP-based coheritability from the linear model are on the case-
control scale and so depend partly on the proportion of cases and controls in the sample.
Transformation to the liability scale allowed benchmarking of  to estimates of
heritability from family studies, and the transformation accounts for the proportion of cases
in the sample and depends on the assumed disorder risk (K). The appropriate choice of K
depends on the definitions of both the phenotype (including ascertainment strategy) and the
population, which might differ between cohorts. We considered lower and upper bounds for
K in Table 1 to cover the range of possible values. rg SNP estimates are independent of scale
and hence are not dependent on the choice of K.
Genome-partitioning linear mixed model
We partitioned the variance explained by the SNPs in several ways. For example, for the
univariate linear model
with
where n is the number of subsets from any non-overlapping partitioning of SNPs; n = 22 for
the joint analysis by chromosome, n = 5 for the analysis by MAF bin and n = 3 for the
analysis of SNP by gene annotation in which SNPs were classed as CNS+ genes (2,725
genes representing 547 Mb), SNPs in other genes (14,804 genes representing 1,069 Mb) and
the remaining SNPs not in genes. Gene boundaries were set at ± 50 kb from the 5̘and 3̘
UTRs of each gene, and CNS+ genes were the four sets identified by Raychaudhuri et al.34
(one set comprised genes expressed preferentially in the brain compared to other tissues, and
the other three sets comprised genes annotated to be involved in neuronal activity, learning
and synapses). The CNS+ set was found to explain more of the SNP-based heritability than
expected by chance for schizophrenia35. All methods have been implemented into the freely
available GCTA software65.
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aSome cohorts include cases and pseudocontrols, where pseudocontrols are the genomic
complements of the cases derived from genotyping of proband-parent trios.
bUsed in Figures 1 and 3 Supplementary Tables 1–8.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Evidence for genome-wide pleiotropy between psychiatric disorders. Proportion of variance
in liability (SNP-based heritability) and proportion of covariance in liability between
disorder (SNP-based coheritability) for five major psychiatric disorders. The 95% error bars
represent the estimates ± 1.96 s.e. SCZ, schizophrenia; MDD, major depressive disorder;
BPD, bipolar disorder.
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Figure 2.
Genomic partitioning of SNP-based heritability and SNP-based coheritability by annotation.
Shown is the proportion of SNPs attributable to genes in the CNS+ set (red), the proportion
of SNP-based heritability attributable to SNPs in the CNS+ set (dark green), the proportion
of SNP-based coheritability attributable to SNPs in the CNS+ set (light green) and the
proportion of SNP-based heritability for Crohn’s disease attributed to SNPs in the CNS+ set
(orange). The 95% error bars represent the estimates ± 1.96 s.e. ***P < 1 × 10−5 in a test of
whether the proportion of heritability explained by SNPs was equal to the proportion of SNP
for the CNS+ set.
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Figure 3.
SNP-based heritabilities and coheritabilities. (a) For each disorder, SNP-based heritabilities
are estimated from univariate analyses of the full data set (dark green) or of sample subsets
(red and pink bars). These heritabilities are also estimated from bivariate analyses in which
different subsets of the same disorder comprise the two traits (blue). Test of the
heterogeneity of estimates, P value for Cochran’s Q: schizophrenia, 0.3; bipolar disorder, 1
× 10−6; major depressive disorder, 4 × 10−3; ADHD, 9 × 10−6; ASD, 0.99; Higgins’ I2:
schizophrenia, 21%; bipolar disorder, 86%; major depressive disorder, 71%; ADHD, 91%;
ASD, 0%). (b) For comparison, the coheritabilities using the full data sets reported in Figure
1 are shown. (c) As a negative control, estimates of coheritabilities with Crohn’s disease, a
disease not expected to be genetically related to psychiatric disorders, are shown. We
estimated 95% error bars using ± 1.96 s.e.
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